Wire Stories

Alico, Inc. Announces Substantial Increase in Dividend, Additional Ranch Land Sales and Update on ESG Initiative

FORT MYERS, Fla., June 14, 2021 (GLOBE NEWSWIRE) -- Alico, Inc. (“Alico” or the “Company”)…

Hisense’s European Sales Revenue Surges to 113%, Successfully Strengthen European Competitive Position and Profitability

QINGDAO, China--(BUSINESS WIRE)--#Hisense--Hisense, the official sponsor of UEFA EURO 2020, celebrates the official kick-off of…

Telix Pharmaceuticals and Applied Radiology Launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research

MELBOURNE, Australia & INDIANAPOLIS--(BUSINESS WIRE)--$TLX #SNMMI--Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announced…

DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Metastatic Breast Cancer

TOKYO & MUNICH, Germany & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo)…

Newborn Screening Test for Sickle Cell Disease Now Supported by Gazelle 8-Minute, Point-of-Care Diagnostic

First worldwide “over-the-air” software enhancement made to Gazelle customer installations PORTLAND, Ore. & MUMBAI--(BUSINESS WIRE)--Hemex…

ICE Reports Record Total Futures and Options Open Interest of 85.8 Million Contracts

Total Open Interest +10% y/y LONDON & NEW YORK & SINGAPORE--(BUSINESS WIRE)--Intercontinental Exchange, Inc. (NYSE:ICE),…

Radware Alert: Fancy Lazarus DDoS Extortion Group is Back with New Campaign Focused on Unprotected Assets Across All Industries

Radware Onboards Numerous Customers with Fancy Lazarus Ransom Letters in Recent Weeks MAHWAH, N.J., June…

Global and Chinese Vacuum Toilet Assembly Industry 2021 Market Research Report – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global and Chinese Vacuum Toilet Assembly Industry, 2021 Market Research Report" report has…

Celltrion announces positive top-line results from global Phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment

Regdanvimab (CT-P59) (40mg/kg) achieved statistically significant and clinically meaningful results in four main endpoints including…